Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Controlled, Multicenter Phase II Clinical Study of Toripalimab Combined With PCb-EC Regimen (Albumin Paclitaxel + Carboplatin Followed by Epirubicin + Cyclophosphamide) or PCb Regimen (Albumin Paclitaxel + Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

NCT07256964 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07256964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Controlled, Multicenter Phase II Clinical Study of Toripalimab Combined With PCb-EC Regimen (Albumin Paclitaxel + Carboplatin Followed by Epirubicin + Cyclophosphamide) or PCb Regimen (Albumin Paclitaxel + Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 26, 2025
Completion date
December 31, 2033
Enrollment
216 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer